NRx Pharmaceuticals, Inc. (NASDAQ:NRXP – Get Free Report) has earned a consensus recommendation of “Hold” from the seven ratings firms that are presently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $34.50.
A number of brokerages have issued reports on NRXP. Weiss Ratings reissued a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research note on Wednesday, August 5th. UBS Group reaffirmed a “buy” rating on shares of NRx Pharmaceuticals in a research note on Wednesday, August 26th. HC Wainwright reiterated a “buy” rating on shares of NRx Pharmaceuticals in a report on Tuesday, August 25th. Wall Street Zen cut shares of NRx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, BTIG Research restated a “buy” rating and issued a $10.00 target price on shares of NRx Pharmaceuticals in a report on Tuesday, August 18th.
Check Out Our Latest Analysis on NRx Pharmaceuticals
NRx Pharmaceuticals Stock Performance
NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) last posted its quarterly earnings data on Monday, August 17th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.33). The firm had revenue of $1.10 million during the quarter, compared to analyst estimates of $1.33 million. As a group, equities research analysts forecast that NRx Pharmaceuticals will post -0.36 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NRXP. Bleakley Financial Group LLC purchased a new stake in NRx Pharmaceuticals during the fourth quarter valued at about $318,000. Ethos Financial Group LLC raised its holdings in shares of NRx Pharmaceuticals by 33.6% in the 1st quarter. Ethos Financial Group LLC now owns 15,900 shares of the company’s stock worth $34,000 after purchasing an additional 4,000 shares during the period. Commonwealth Equity Services LLC acquired a new position in shares of NRx Pharmaceuticals in the 4th quarter valued at about $994,000. Anson Funds Management LP lifted its stake in shares of NRx Pharmaceuticals by 50.3% in the 4th quarter. Anson Funds Management LP now owns 3,043,957 shares of the company’s stock valued at $8,249,000 after purchasing an additional 1,018,853 shares in the last quarter. Finally, Global Retirement Partners LLC purchased a new stake in shares of NRx Pharmaceuticals during the 4th quarter worth about $107,000. Institutional investors and hedge funds own 4.27% of the company’s stock.
NRx Pharmaceuticals Company Profile
NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.
Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.
Featured Articles
- Five stocks we like better than NRx Pharmaceuticals
- Why Bitcoin ETFs May Be Worth Another Look as Inflows Rebound
- 3 Small-Cap Biotechs With Binary Catalysts on the Calendar
- Planet Labs Has Fallen Back to Earth, But Wall Street Still Sees a Rebound
- As Homeowners’ Premiums Surge, This Insurer Is Posting Record Profits
Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
